Grupo Biotoscana and EISAI sign exclusive licensing agreement for four products

GBT-Grupo Biotoscana (B3: GBIO33), a leading biopharmaceutical company in Latin America, today announced that it has entered into an exclusive licensing agreement with Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo, Japan-based Eisai Co., Ltd., to commercialize HALAVEN® (eribulin mesylate), LENVIMA® (lenvatinib), FYCOMPA® (perampanel) and INOVELON® (rufinamide) throughout Latin America, including Brazil, Argentina and Mexico. However, Eisai will retain the rights to Halaven and Lenvima in Mexico, and will seek to continue to build upon the growth of its oncology business in this country.

Under the new agreement, GBT will be responsible for marketing authorizations, market access, commercialization, distribution throughout Latin America.

“We are honored to be partnering with Eisai, one of the leading research-based companies in the world, in order to help expand the usage of Halaven, Lenvima, Fycompa and Inovelon, four compounds that bring new hope for patients with debilitating diseases in Latin America,” said Mariano García-Valiño, CEO of Grupo Biotoscana. “We are also excited to continue building on the success of Halaven and Lenvima in Brazil, as well as to expand the reach of Eisai’s oncology and neurology products through future launches in Latin America. We believe this partnership will be key for GBT, and it reinforces our position as the partner of choice for cutting-edge medicines in Latin America.”

“We are excited to collaborate with Grupo Biotoscana, a company with an extensive reach in the Latin American market,” said Shaji Procida, President and COO of Eisai Inc. “This agreement will provide important therapeutic options for patients in need in a number of countries where they currently remain unavailable.”

See the full article.

About GBT
GBT-Grupo Biotoscana (GBT) is a biopharmaceutical group that operates in the fast-growing Latin American region and focuses on rapidly growing market segments such as infectious diseases, oncology and onco-hematology, special treatments, immunology and inflammation and orphan/rare diseases, among others. GBT is currently present throughout 10 Latin American countries where it operates under its companies Biotoscana, United Medical and LKM. GBT’s strong portfolio combines world-class licenses and proprietary products.

To find out more about Grupo Biotoscana, please go to

About Eisai Inc.
At Eisai Inc., human health care (hhc) is our goal. We give our first thoughts to patients and their families, and helping to increase the benefits health care provides. As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., we have a passionate commitment to patient care that is the driving force behind our efforts to discover and develop innovative therapies to help address unmet medical needs.
Eisai is a fully integrated pharmaceutical business that operates in two global business groups: oncology and neurology (dementia-related diseases and neurodegenerative diseases). Each group functions as an end-to-end global business with discovery, development, and marketing capabilities. Our U.S. headquarters, commercial and clinical development organizations are located in New Jersey; our discovery labs are in Massachusetts and Pennsylvania; and our global demand chain organization resides in Maryland and North Carolina. To learn more about Eisai Inc., please visit us at and follow us on Twitter and LinkedIn.

About Eisai Co., Ltd.
Eisai Co., Ltd. is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit

HALAVEN® (eribulin) is a synthetic derivative of halichondrin B, a natural marine product derived from the sea sponge Halichondria okadai. It is a new anticancer treatment that acts against tumors by suppressing the growth of microtubules by blocking the polymerization of tubulin, a structural component of microtubules, thereby impeding cellular mitosis. Currently approved in more than 60 countries and territories worldwide for the treatment of metastatic breast cancer and advanced liposarcoma.

LENVIMA® (lenvatinib) is a novel multiple receptor tyrosine kinase inhibitor (orally administered molecular-targeted agent) discovered and developed by Eisai. Launched as a treatment for refractory thyroid cancer in the United States, Japan and Europe in 2015 and has been granted orphan drug status (a drug for rare diseases) for the treatment of thyroid cancer by the regulatory authorities in each of these regions. LENVIMA® is also indicated to treat adults with a form of advanced kidney cancer.

FYCOMPA® (perampanel) is an antiepileptic agent. Believed to exert its antiepileptic effect by selectively antagonizing AMPA receptors, which are a type of neuroreceptor that binds with neurotransmitter glutamic acid, thus preventing excess influx of calcium into cells and suppressing the aggravation of excited nerve cells.

INOVELON® (rufinamide) is an antiepileptic agent created by Novartis that possesses novel triazole derivative structure and extensive anticonvulsant effects. It is marketed in Europe, the United States and Japan as an adjunctive therapy for Lennox-Gastaut syndrome (LGS), one of the most severe and intractable forms of childhood-onset epilepsy. It is sold under the name BANZEL® in the United States and Canada.

Forward-Looking Statements (GBT)

This release includes forward-looking statements concerning a transaction between GBT-Grupo Biotoscana and EISAI, including expectations regarding the applicability of predictions to the commercialization of certain products. GBT-Grupo Biotoscana disclaims any obligation to update any forward-looking statement, except as required by applicable law.